Another UK Biotech Runs Aground
Renovo's Juvista Tanks in Phase III; Stock plunges 75%
By Nuala Moran
Monday, February 14, 2011
LONDON Renovo plc is weighing its options, including that of winding up the company, after its lead scar-improving product Juvista failed in the pivotal Phase III European trial. Shares (LSE:RNVO) in the Manchester, UK-based company fell 75 percent to 17 pence when the news was announced on Friday afternoon.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.